JUVÉDERM pozycji w ofercie ALLPARA do użytku profesjonalnego, kupowanych bezpośrednio i z certyfikatem przy każdej wysyłce.
HArmonyCa Lidocaine
HArmonyCa Lidocaine is a hybrid hyaluronic acid and calcium hydroxyapatite injectable facial implant for the Allergan Aesthetics range, intended for facial soft tissue augmentation. It is suitable for authorised medical practitioners, who place it in the deep dermal and sub-dermal layers of the mid and lower face, where the hyaluronic acid provides an immediate lifting and volumising effect and the calcium hydroxyapatite microspheres support sustained collagen stimulation, so one treatment gives both an instant result and progressive structural support. The product contains calcium hydroxyapatite microspheres of 25 to 45 microns at 55.7%, cross-linked sodium hyaluronate gel at 20 mg/mL, phosphate buffer and lidocaine hydrochloride at 3 mg/mL (0.3%) to reduce pain during treatment, and it is a CE-marked medical device for professional use by authorised medical practitioners only. It is supplied as two 1.25 mL pre-filled glass syringes with two single-use 27G half-inch thin-wall sterile needles.
Najważniejsze zalety: HArmonyCa Lidocaine
- Provides an immediate lifting and volumising effect through hyaluronic acid
- Supports sustained collagen stimulation through calcium hydroxyapatite
- Combines hyaluronic acid and calcium hydroxyapatite in one ready-to-use injectable
- Designed for facial soft tissue augmentation in the deep dermal and sub-dermal layers
- Contains 0.3% lidocaine hydrochloride to reduce pain during treatment
- Supplied as two 1.25 mL pre-filled syringes with two 27G thin-wall needles
- CE-marked medical device
Wskazania i zastosowanie profesjonalne
Główne wskazania
- Facial soft tissue augmentation
- Deep dermal and sub-dermal facial volume augmentation
Zastosowanie profesjonalne
For use only by authorised medical practitioners in accordance with local regulation, under sterile conditions, following clinical assessment. Single use, single patient; do not re-sterilise. Insert at approximately 30 degrees into the deep dermis with the bevel oriented downwards, using a linear threading technique, and cross-hatching in layers where larger volumes are required. Aspirate before injecting. Subsequent treatments may be required, with at least seven days between treatments to allow evaluation of the outcome, and at least four weeks between ultrasound-based, laser or peeling treatments and use of this product. It is contraindicated in pregnancy or breastfeeding, in patients under 18, in patients with known sensitivity to any product component or to lidocaine or other amide-type local anaesthetics, and in patients with conditions for which lidocaine is contraindicated. It is also contraindicated in skin disease or abnormal skin conditions, acute or chronic infection or inflammation at or near the treatment site, susceptibility to keloid or hypertrophic scarring, impaired wound healing, prolonged bleeding, a history of anaphylaxis or multiple severe allergies, known sensitivity to steroids, herpes, and autoimmune disease. It must not be injected into the glabellar or periocular areas, the lips or perioral region, regions containing foreign bodies, blood vessels or highly vascularised areas, or the epidermis or superficial dermis.
Obszary zabiegowe
- Mid and lower face
- Cheek lines
- Lower-face contour and sagginess
- Skin firmness
Profil pacjenta
Patients aged 18 years or older who are suitable for facial soft tissue augmentation following clinical assessment by an authorised medical practitioner. Contraindicated during pregnancy and breastfeeding, and in patients meeting the other exclusion criteria, including known sensitivity to any product component or to amide-type local anaesthetics. Safety and efficacy have not been evaluated in diabetic patients, in patients who previously received other filling implants, or in patients with a history of keloid formation, connective tissue disease, active bleeding disorders, active hepatitis, cancer, stroke or myocardial infarction, or on immunosuppressive therapy.
Jak działa HArmonyCa Lidocaine
HArmonyCa combines cross-linked hyaluronic acid and calcium hydroxyapatite in a single injectable. The hyaluronic acid component provides an immediate lifting and volumising effect, while the calcium hydroxyapatite microspheres, at 25 to 45 microns and 55.7% of the formulation, support sustained collagen stimulation and provide progressive structural support after treatment. The 0.3% lidocaine hydrochloride reduces pain during treatment. The implant is placed in the deep dermal and sub-dermal layers and is biodegradable.
Dlaczego warto zamawiać w Allpara
Allpara oferuje oryginalne, sprawdzone produkty HARMONYCA od zweryfikowanych dostawców, z pełną identyfikowalnością partii i wsparciem ekspertów. Obsługujemy kliniki i specjalistów medycyny estetycznej, oferując produkty z certyfikatem CE, szybką dostawę na terenie całej UE z naszego magazynu w UE oraz konkurencyjne ceny hurtowe. Najważniejsze są dla nas bezpieczeństwo, satysfakcja i efekty Twoich pacjentów - z dedykowanym wsparciem posprzedażowym dla Twojego spokoju.
Najczęściej zadawane pytania
What is in HArmonyCa?
Calcium hydroxyapatite microspheres of 25 to 45 microns diameter at 55.7%, suspended in a cross-linked sodium hyaluronate gel at 20 mg/mL from a non-animal source, with a phosphate buffer and lidocaine hydrochloride at 3 mg/mL.
How does HArmonyCa differ from a standard hyaluronic acid filler?
HArmonyCa combines cross-linked hyaluronic acid for immediate volume with calcium hydroxyapatite microspheres for sustained collagen stimulation, giving it a dual mechanism that standard single-ingredient hyaluronic acid fillers do not have.
How often can HArmonyCa be repeated?
Subsequent treatments may be required to obtain optimal results, with at least seven days between treatments so the outcome of the implantation can be evaluated.
Więcej od Allergan
Alternatywy dla kliniki
Wróć tam, gdzie skończyłeś
HArmonyCa Lidocaine
HArmonyCa Lidocaine is a hybrid hyaluronic acid and calcium hydroxyapatite injectable facial implant for the Allergan Aesthetics range, intended for facial soft tissue augmentation. It is suitable for authorised medical practitioners, who place it in the deep dermal and sub-dermal layers of the mid and lower face, where the hyaluronic acid provides an immediate lifting and volumising effect and the calcium hydroxyapatite microspheres support sustained collagen stimulation, so one treatment gives both an instant result and progressive structural support. The product contains calcium hydroxyapatite microspheres of 25 to 45 microns at 55.7%, cross-linked sodium hyaluronate gel at 20 mg/mL, phosphate buffer and lidocaine hydrochloride at 3 mg/mL (0.3%) to reduce pain during treatment, and it is a CE-marked medical device for professional use by authorised medical practitioners only. It is supplied as two 1.25 mL pre-filled glass syringes with two single-use 27G half-inch thin-wall sterile needles.
Najważniejsze zalety: HArmonyCa Lidocaine
- Provides an immediate lifting and volumising effect through hyaluronic acid
- Supports sustained collagen stimulation through calcium hydroxyapatite
- Combines hyaluronic acid and calcium hydroxyapatite in one ready-to-use injectable
- Designed for facial soft tissue augmentation in the deep dermal and sub-dermal layers
- Contains 0.3% lidocaine hydrochloride to reduce pain during treatment
- Supplied as two 1.25 mL pre-filled syringes with two 27G thin-wall needles
- CE-marked medical device
Wskazania i zastosowanie profesjonalne
Główne wskazania
- Facial soft tissue augmentation
- Deep dermal and sub-dermal facial volume augmentation
Zastosowanie profesjonalne
For use only by authorised medical practitioners in accordance with local regulation, under sterile conditions, following clinical assessment. Single use, single patient; do not re-sterilise. Insert at approximately 30 degrees into the deep dermis with the bevel oriented downwards, using a linear threading technique, and cross-hatching in layers where larger volumes are required. Aspirate before injecting. Subsequent treatments may be required, with at least seven days between treatments to allow evaluation of the outcome, and at least four weeks between ultrasound-based, laser or peeling treatments and use of this product. It is contraindicated in pregnancy or breastfeeding, in patients under 18, in patients with known sensitivity to any product component or to lidocaine or other amide-type local anaesthetics, and in patients with conditions for which lidocaine is contraindicated. It is also contraindicated in skin disease or abnormal skin conditions, acute or chronic infection or inflammation at or near the treatment site, susceptibility to keloid or hypertrophic scarring, impaired wound healing, prolonged bleeding, a history of anaphylaxis or multiple severe allergies, known sensitivity to steroids, herpes, and autoimmune disease. It must not be injected into the glabellar or periocular areas, the lips or perioral region, regions containing foreign bodies, blood vessels or highly vascularised areas, or the epidermis or superficial dermis.
Obszary zabiegowe
- Mid and lower face
- Cheek lines
- Lower-face contour and sagginess
- Skin firmness
Profil pacjenta
Patients aged 18 years or older who are suitable for facial soft tissue augmentation following clinical assessment by an authorised medical practitioner. Contraindicated during pregnancy and breastfeeding, and in patients meeting the other exclusion criteria, including known sensitivity to any product component or to amide-type local anaesthetics. Safety and efficacy have not been evaluated in diabetic patients, in patients who previously received other filling implants, or in patients with a history of keloid formation, connective tissue disease, active bleeding disorders, active hepatitis, cancer, stroke or myocardial infarction, or on immunosuppressive therapy.
Jak działa HArmonyCa Lidocaine
HArmonyCa combines cross-linked hyaluronic acid and calcium hydroxyapatite in a single injectable. The hyaluronic acid component provides an immediate lifting and volumising effect, while the calcium hydroxyapatite microspheres, at 25 to 45 microns and 55.7% of the formulation, support sustained collagen stimulation and provide progressive structural support after treatment. The 0.3% lidocaine hydrochloride reduces pain during treatment. The implant is placed in the deep dermal and sub-dermal layers and is biodegradable.
Dlaczego warto zamawiać w Allpara
Allpara oferuje oryginalne, sprawdzone produkty HARMONYCA z pełną identyfikowalnością partii, produktami z certyfikatem CE, szybką dostawą na terenie całej UE i fachowym wsparciem posprzedażowym.
Najczęściej zadawane pytania
What is in HArmonyCa?
Calcium hydroxyapatite microspheres of 25 to 45 microns diameter at 55.7%, suspended in a cross-linked sodium hyaluronate gel at 20 mg/mL from a non-animal source, with a phosphate buffer and lidocaine hydrochloride at 3 mg/mL.
How does HArmonyCa differ from a standard hyaluronic acid filler?
HArmonyCa combines cross-linked hyaluronic acid for immediate volume with calcium hydroxyapatite microspheres for sustained collagen stimulation, giving it a dual mechanism that standard single-ingredient hyaluronic acid fillers do not have.
How often can HArmonyCa be repeated?
Subsequent treatments may be required to obtain optimal results, with at least seven days between treatments so the outcome of the implantation can be evaluated.